



**EXPAREL**<sup>®</sup>  
(bupivacaine liposome injectable suspension)

OPIOID FREE

## EFFECTIVE JANUARY 1, 2019 CMS APPROVES REIMBURSEMENT FOR EXPAREL IN ASCs

### What can you do now to prepare for reimbursement?

- If you are currently using EXPAREL in an ambulatory surgery center (ASC),
  - Provide the ASC Administrator with a list of surgical procedures performed on Medicare patients who may immediately benefit from a non-opioid postsurgical pain management option
  - Ask the ASC Administrator today to ensure there is a process in place to ensure that **C9290** is billed for all patients who receive EXPAREL
  - Follow up with your ASC Administrator to confirm all commercial payors have been contacted to determine which payors will reimburse for EXPAREL
  - Request that the ASC Administrator provide a list of all commercial payors that have confirmed access to reimbursement for EXPAREL

For details and guidance (referred to as **C9290 Implementation Guidance**) on how to access Medicare reimbursement and engage your commercial payors, please visit [www.EXPAREL.com/reimbursement](http://www.EXPAREL.com/reimbursement).

- If you are currently an EXPAREL user in an acute care setting and would like to learn more about how EXPAREL can be used in the ASC setting, please contact 1-855-RX-EXPAREL (1-855-793-9727) or [reimbursement@pacira.com](mailto:reimbursement@pacira.com) and you will be contacted by your local Pacira representative
- If you are not currently an EXPAREL user and are interested in a non-opioid-based postsurgical pain management option, please contact 1-855-RX-EXPAREL (1-855-793-9727) or [reimbursement@pacira.com](mailto:reimbursement@pacira.com) and you will be contacted by your local Pacira representative

Please see Indication and Important Safety Information on reverse and refer to accompanying full Prescribing Information.

**C9290**  
SURGEONS AND ANESTHESIOLOGISTS



## EXPAREL®

(bupivacaine liposome injectable suspension)

OPIOID FREE

### Indication

EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

### Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

### Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks **other than interscalene brachial plexus nerve block**, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

### Warnings and Precautions for Bupivacaine-Containing Products

**Central Nervous System (CNS) Reactions:** There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

**Cardiovascular System Reactions:** Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death.

**Allergic Reactions:** Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

**Chondrolysis:** There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

**Methemoglobinemia:** Cases of methemoglobinemia have been reported with local anesthetic use.

**Please refer to accompanying full Prescribing Information.**

**For more information, please visit [www.EXPAREL.com](http://www.EXPAREL.com) or call 1-855-RX-EXPAREL (793-9727).**

